Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
OHE Publishes in the Journal of Comparative Effectiveness Research: Future Expectations of Evidence of Relative Effectiveness in Europe and Comparative Effectiveness in the USA in 2020
15 April 2015
Articles co-authored by Adrian Towse, Martina Garau, Donna Messner, and Penny Mohr exploring future expectations of drug relative effectiveness in Europe and comparative effectiveness in the…
New Business Models for Antibiotics. What Can We Learn from Other Industries?
7 April 2015
The business model for antibiotics is broken. We looked at other industries facing conceptually similar challenges – particularly when the incentive for R&D is delinked from…
Medical Research: How Long Does it Take?
10 February 2015
It is surprisingly hard to measure how long medical research takes. A recently published study by OHE, Brunel and RAND Europe shows a better way to…
Benefiting Sooner from Medical Research
3 February 2015
Recently published study by OHE, Brunel University, RAND Europe and Kings College London analyses time lags in medical research and where to shorten them.
Dementia: The R&D Landscape
1 November 2015
This OHE Research Paper provides an overview of the current dementia R&D landscape. The research was undertaken by OHE for Imperial College and the UK Department of Health.
OHE at ISPOR Europe: Presentations
19 November 2014
The OHE gave the following presentations at ISPOR 17th Annual European Congress in Amsterdam, The Netherlands.
Bengt Jönsson Honoured for Contribution to Health Economics
6 August 2014
Launched at a seminar in his honour May 2014, Portrait of a Health Economist: Essays by Colleagues and Friends of Bengt Jönsson is an impressive collection…
Interdependencies in Funding Medical Research in the UK
2 July 2014
Cancer Research UK has recently released a report completed for it by OHE and the Science Policy Research Unit (SPRU) at the University of Sussex that…
How Will Demands for Effectiveness Evidence Change Drug Development?
23 April 2014
Interviews with 19 senior pharma execs suggest how and to what extent effectiveness research may be integrated into drug development. Changes in the clinical and economic…